{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=29", "query": { "condition": "Solid Malignancy", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 5456, "total_pages": 546, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T17:13:16.458Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02044861", "title": "Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "PFK-158", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Cancer Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2014-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-06-23", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Louisville, Kentucky • Houston, Texas + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02044861" }, { "nct_id": "NCT00227786", "title": "Primary Care Physicians' Use of Stop-Smoking Plans to Help Patients Who Are Smokers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tobacco Use Disorder", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "smoking cessation intervention", "type": "BEHAVIORAL" }, { "name": "counseling intervention", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "2003-01", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2013-08-16", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 5, "location_summary": "Aurora, Colorado • Honolulu, Hawaii • Boston, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227786" }, { "nct_id": "NCT00004927", "title": "BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": "2002-10", "has_results": false, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 2, "location_summary": "Detroit, Michigan • New York, New York", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004927" }, { "nct_id": "NCT00096005", "title": "Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "AIDS-related Peripheral/Systemic Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2004-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-24", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096005" }, { "nct_id": "NCT03833427", "title": "Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2019-03-18", "completion_date": "2022-06-28", "has_results": true, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 4, "location_summary": "Duarte, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03833427" }, { "nct_id": "NCT05002270", "title": "JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "NSCLC", "CRC" ], "interventions": [ { "name": "JAB-21822 (KRAS G12C inhibitor)", "type": "DRUG" }, { "name": "Cetuximab (EGFR inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-09-03", "completion_date": "2025-02-12", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05002270" }, { "nct_id": "NCT02154022", "title": "Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Solid Tumors", "Neoplasm" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 100, "start_date": "2014-07-31", "completion_date": "2030-05-01", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02154022" }, { "nct_id": "NCT00803556", "title": "Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Breast Cancer" ], "interventions": [ { "name": "Alvespimycin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2006-01", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2011-06-27", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • New York, New York", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00803556" }, { "nct_id": "NCT02012231", "title": "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Thyroid Cancer", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Cholangiocarcinoma", "Histiocytosis", "Hairy Cell Leukemia" ], "interventions": [ { "name": "PLX8394", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fore Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-02", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02012231" }, { "nct_id": "NCT05074472", "title": "A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Pancreatic Ductal; Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Biliary Cancer Metastatic", "Ovarian Serous Cystadenocarcinoma" ], "interventions": [ { "name": "ZB131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ZielBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2022-01-14", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2024-01-29", "last_synced_at": "2026-10-25T17:13:16.458Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05074472" } ] }